StockNews.AISignal intelligence
Company intelligence

RARE

Ultragenyx Pharmaceutical Inc. · NASDAQ · Healthcare

Price$16.52-4.09% · −$0.71
Market cap1.68BEquity value
P / E-2.8Trailing ratio
Volume876.38KLatest session
Market data

RARE price chart

TradingView
Related signals
1 min delayed

Browse public RARE signals with their source context and measured market impact. Open any signal for its permanent analysis page.

RARESep 17, 2026+5.22% since signal

FDA Approval of Ultragenyx Gene Therapy Acts as Key Rare-Disease Catalyst

The FDA approval of Ultragenyx's gene therapy for a rare, fatal disease marks a pivotal regulatory milestone for the company. The article provides no product name or disease indication, limiting near-term revenue visibility, but the approval could lift sentiment and valuation if the addressable market is meaningful. The catalyst is regulatory in nature and may translate into a short-term stock move with subsequent focus on pricing and commercialization details.

View signal analysis
RARESep 2, 2026-44.03% since signal

Ultragenyx late-stage failure weighs on RARE stock and pipeline

Ultragenyx announced that its experimental therapy for a rare genetic neurodevelopmental disorder failed to meet the primary endpoint in a pivotal late-stage trial, triggering a sharp after-hours stock drop. The setback undermines near-term pipeline value and may force strategic reprioritization and cost considerations as investors reassess Ultragenyx's long-term growth prospects.

View signal analysis
Research

Company intelligence